Drug intelligence / Profile preview

ML-004

Development stage: Phase 2
Lead developer: MapLight Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ML-004 is an investigational, orally administered small molecule drug developed by MapLight Therapeutics for the treatment of autism spectrum disorder (ASD), specifically targeting social communication deficits and irritability. It is a bilayer immediate-release/extended-release tablet designed for once-daily dosing, with dose strengths of 12 mg and 24 mg. The mechanism of action is as a selective serotonin 5-HT1B receptor agonist, aiming to modulate serotonergic signaling in the brain to improve symptoms associated with ASD. Clinical development has reached Phase 2 trials in adolescents and adults with ASD. There are no FDA approvals or brand names currently associated with this compound[1][3][4][5][7].

Other names: ML 004ML004ML-004

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)

Beyond the preview

Go deeper on ML-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ML-004.

Explore the full profile